Kura Oncology, Inc.
kuraoncology.comWhat Do They Do?
Sells KOMZIFTI, an oral cancer medicine for adults with a specific form of leukemia, and develops small-molecule treatments for other cancers and diseases.
10-K for FY2025, filed Mar 5, 2026We are a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Since our…View ↗
2025 was a pivotal year for our company. On November 13, 2025, the FDA approved our new drug application, or NDA, for ziftomenib, which is…View ↗
We also are exploring the use of KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and…View ↗
In addition to our menin inhibitor programs, we are evaluating farnesyl transferase inhibitors, or FTIs, in combination with various…View ↗
How Do They Make Money?
Collaboration partners pay for licensed rights and related work through upfront fees, cost reimbursements, milestone payments and royalties on product sales. Specialty distributors and pharmacies pay for KOMZIFTI when it is delivered.
10-K for FY2025, filed Mar 5, 2026
-
10-K for FY2025, filed Mar 5, 2026
FY2025 revenue by product or service ↗
$67.5M
-
10-K for FY2025, filed Mar 5, 2026
$67.5M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product revenue, net
Sold outright
10-K for FY2025, filed Mar 5, 2026 |
3.2% |
Product revenue, net, FY2025
$2.1M Sources
|
Sold outright |
|
Collaboration Revenue
Licensed
10-K for FY2025, filed Mar 5, 2026 |
97% |
Collaboration Revenue, FY2025
$65.4M Sources
|
Licensed |
Who Are Their Customers?
In the United States, specialty distributors and specialty pharmacies buy KOMZIFTI and resell it to pharmacies, health care providers and patients. Kyowa Kirin handles ziftomenib commercialization outside the United States.
10-K for FY2025, filed Mar 5, 2026
Do Revenues Turn Into Profits?
No. It lost $278.7M in FY2025.
10-K for FY2025, filed Mar 5, 2026
−$303.6MView ↗
10-K for FY2025, filed Mar 5, 2026
−$278.7MView ↗
10-K for FY2025, filed Mar 5, 2026
−$70.7MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 12, 2026
−$68.3MView ↗
- ▲ +3% (Loss)
- vs −$66.1M in Q2 FY2025
10-Q for Q2 FY2026, filed Aug 12, 2026
Open tableView ↗
-
Sep 8, 2026
Jennifer Fulk appointed chief financial officer
Sources
8-K, filed Sep 8, 2026
Effective as of September 8, 2026, the Board of Directors (the “Board”) of Kura Oncology, Inc. (the “Company”) appointed Jennifer Fulk as…View ↗
From development to sales
Kura has moved from clinical-stage drug development to commercialization, with KOMZIFTI approved and marketed in the United States while it continues developing a pipeline.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Mar 5, 2026We are a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer.…View ↗
We are a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Since our…View ↗
2025 was a pivotal year for our company. On November 13, 2025, the FDA approved our new drug application, or NDA, for ziftomenib, which is…View ↗
We initiated commercial sales of KOMZIFTI in the United States on November 21, 2025. Under the terms of the Kyowa License Agreement, we…View ↗
Beyond cancer
The earlier report focused on anti-cancer drugs; the latest report also describes exploring a menin inhibitor for diabetes and cardiometabolic disorders.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Mar 5, 2026Our strategy is to discover, acquire, develop and commercialize innovative anti-cancer agents in oncology indications with significant…View ↗
We also are exploring the use of KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and…View ↗
Who Do They Compete With?
Competes with Syndax, Janssen, Dainippon Sumitomo, Servier, Biomea Fusion, CHARM Therapeutics, Abbvie, Genentech, Novartis, Astellas, BMS, Rigel, and Daiichi-Sankyo
10-K for FY2025, filed Mar 5, 2026We are aware of other companies with competing commercial or clinical-stage menin inhibitor programs, including Syndax, Janssen (Johnson &…View ↗
Loading...
